-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
See You in Seoul: Inside WCLC 2026
Hear from the Conference Chairs as they discuss networking opportunities, new session formats, and more.
-
Amazing Case Race Returns to WCLC 2026
Alan Nguyen, IASLC Education Coordinator, shares how the interactive competition has grown in both participation and diversity of perspectives from around the globe.
-
Next Stop: Seoul and the 2026 World Conference on Lung Cancer
Hit the ground running in Seoul with this guide to important travel requirements and tips for navigating public transportation in the city.
-
Challenge Accepted: Move, Connect, and Win Prizes in Seoul
Turn your steps and other wellness activities into points at WCLC 2026 by participating in the IASLC Wellness Challenge.
-
Celebrate 20 years of the Journal of Thoracic Oncology
Under the leadership of Drs. James R. Jett and Alex A. Adjei, the IASLC’s flagship journal has expanded its influence on thoracic oncology, with its Impact Factor growing from an initial 1.49 in 2007 to 23.3 in its 20th year.
-
Encore: WCLC Talent Showcase Returns as Two Familiar Faces Prepare to Take the Stage Again
Ahead of WCLC 2026, Dr. Henry Park reflects on participating in the inaugural Talent Showcase in Barcelona and shares what he is looking forward to about performing alongside Dr. Rimner again in Seoul.
-
ctDNA-Guided Adaptive De-escalation Therapy for Advanced NSCLC: Ready for Prime Time?
In a recent commentary, Drs. Roberto Borea and Christian Rolfo analyze the findings from a nonrandomized controlled trial and address the feasibility of ctDNA-guided targeted therapy in patients with advanced non-small cell lung cancer.
-
AI and the Diagnosis of TETs: Teaching Machines to See What Pathologists See
Drs. Marina Chiara Garassino and Erica Pietroluongo discuss the potential of deep learning models as a diagnostic tool for the classification of thymic epithelial tumors.
-
Timing is of the Essence: Commentary on NRG/Alliance LU005 Results
While the trial did not yield a survival benefit, Dr. Adam Schoenfeld says the study strengthens the case that immunotherapy timing and sequencing matter.
-
Successive Versions of the Same Topic: Translating Data From ASCO 2026
In part 2 of his editorial, Dr. Gilberto Lopes reports on additional breaking data from the ASCO 2026 Annual Meeting, highlighting the latest EGFR research reported from several key trials.
View ILCN Archives
Provider Resources
Popular Articles